Danco Laboratories and GenBioPro filed emergency Supreme Court applications to restore mail‑order mifepristone after a 5th Circuit block.
The 5th Circuit decision temporarily halted deliveries, threatening a key abortion method used in about two‑thirds of U.S. abortions.
Louisiana challenged the 2023 FDA rule lifting in‑person dispensing, citing sepsis and hemorrhage risks.
The ruling could impact FDA autonomy, GenBioPro’s revenue—mifepristone is its main product—and abortion‑access politics before November midterms.